IKARIAN CAPITAL LLC
Q3 2026 Form 13-F
DALLAS, TEXAS
CIK 0001778253
· CRD 281880
· SEC-registered investment adviser
$994.2M Reported Value Total
IKARIAN CAPITAL reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $697,961,635, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $564.0M gross asset value
Hedge Fund: $564.0M
Source: Form ADV filed 2026-05-20
Reported value
$994.2M
Quarter over quarter
-8.8%
Holdings
125
Top-10 concentration
38.2%
Key People
Form ADV owners & control persons
Ryan David Atwell
CONTROLLER
Matthew G Hale
DEPUTY COMPLIANCE OFFICER
David Edward Kaufman
DIRECTOR OF BUSINESS DEVELOPMENT AND INVESTOR RELATIONS
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $994.2M |
| Positions | 125 |
| Change in reported value | +7.1% |
| New positions | 19 |
| Exited positions | 20 |
| Position turnover | 26.9% |
| Top-10 concentration | 38.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
125 | $994.2M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
126 | $928.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
127 | $1.2B |
|
Q4 2025 13F
Filed Feb 18, 2026
|
135 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
116 | $990.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
103 | $520.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
116 | $811.5M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
122 | $735.3M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
96 | $717.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
85 | $574.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
82 | $912.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
78 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
81 | $831.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
81 | $627.9M |
|
Q1 2023 13F
Filed May 15, 2023
|
90 | $440.7M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
66 | $414.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
64 | $501.8M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
97 | $548.4M |
|
Q1 2022 13F
Filed May 13, 2022
|
153 | $760.5M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
149 | $671.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MRNA P MODERNA INC | $77.0M | 7.75% |
| 2 | BMY P BRISTOL-MYERS SQUIBB CO | $61.9M | 6.23% |
| 3 | KOD KODIAK SCIENCES INC | $50.5M | 5.08% |
| 4 | XBI P SPDR SERIES TRUST | $47.3M | 4.76% |
| 5 | PRAX C PRAXIS PRECISION MEDICINES I | $29.1M | 2.92% |
| 6 | ABVX ABIVAX SA | $28.4M | 2.86% |
| 7 | IRON P DISC MEDICINE INC | $25.5M | 2.56% |
| 8 | PCVX VAXCYTE INC | $22.8M | 2.29% |
| 9 | RCUS ARCUS BIOSCIENCES INC | $19.0M | 1.91% |
| 10 | INCY P INCYTE CORP | $18.2M | 1.83% |
| 11 | ACAD C ACADIA PHARMACEUTICALS INC | $17.1M | 1.72% |
| 12 | PCVX P VAXCYTE INC | $17.1M | 1.72% |
| 13 | CLDX CELLDEX THERAPEUTICS INC NEW | $16.8M | 1.69% |
| 14 | AMLX AMYLYX PHARMACEUTICALS INC | $16.3M | 1.64% |
| 15 | PHVS PHARVARIS N V | $15.9M | 1.6% |
| 16 | KYMR P KYMERA THERAPEUTICS INC | $14.9M | 1.5% |
| 17 | KOD C KODIAK SCIENCES INC | $14.2M | 1.43% |
| 18 | IRON C DISC MEDICINE INC | $13.1M | 1.32% |
| 19 | VERA VERA THERAPEUTICS INC | $12.9M | 1.3% |
| 20 | ANRO ALTO NEUROSCIENCE INC | $12.3M | 1.24% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.